AnaptysBio announces $75,000,000 stock repurchase plan, with strong cash position and sales milestone

From GlobeNewswire: 2025-03-24 09:15:00

AnaptysBio, Inc. announced a Stock Repurchase Plan to buy back up to $75,000,000 of its common stock. The company has over $420 million in cash and expects a $75 million sales milestone payment from GSK. The shares can be repurchased through various means, with the plan expiring on December 31, 2025. Anaptys focuses on immunology therapeutics for autoimmune diseases, with lead program rosnilimab in Phase 2 trials for rheumatoid arthritis and ulcerative colitis. The company also has antibodies licensed to GSK for immuno-oncology. Forward-looking statements caution risks and uncertainties. Contact Executive Director, Investor Relations for more information.



Read more at GlobeNewswire: Anaptys Announces Stock Repurchase Plan